Relationship between advanced glycogen endproduct level measured by non-invasive fluorescent AGE analyzer and FGM-monitored glycemic fluctuations in type 2 diabetes

Relationship between advanced glycogen endproduct level measured by non-invasive fluorescent AGE analyzer and FGM-monitored glycemic fluctuations in type 2 diabetes - Relationship between advanced glycogen endproduct level measured by non-invasive fluorescent AGE analyzer and FGM-monitored glycemic fluctuations in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047750

Enrollment

Registered

2022-05-30

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The selection criteria for the subjects are as follow. 1. Patients who have been diagnosed as type 2 diabetes. 2. Regardless of gender

Exclusion criteria

Exclusion criteria: The exclusion criteria for the subjects are as follow. 1. Subjects with acute and/or chronic inflammation 2. Subjects with fresh cardiovascular and/or cerebrovascular diseases 3. Subjects with liver cirrhosis. 4. Subjects with severe respiratory disease or severe heart failure 5. Subjects with alcoholicsm or medicinal intoxication 6. Subjects with psychosis 7. Subjects who doctors judge as unfitness

Design outcomes

Primary

Measure	Time frame
The correlation between the AGE measurement value using the fingertip AGE sensor and the blood glucose fluctuation range or the number and time of hypoglycemia	—

Secondary

Measure	Time frame
1: Correlation between AGE measurements using the fingertip AGE sensor and various parameters as follow; 1. fasting plasma glucose 2. HbA1c 3. glycated albumin 4. systolic blood pressure 5. diastolic blood pressure 6. serum lipid profiles 7. eGFR (ml/min/1.73m2) 8. Liver function: AST, ALT, GGT 9. weight, BMI 10. serum Albumin 11. ACR(Urinary-albumin/creatinine ratio) 12. T-Bil 13. HOMA-R 14. hs-CRP 15. mean-IMT, max-IMT, plaque score 16. ABI, baPWV 17. counts of leukocyte and its fraction 18. history of retinopathy, neuropathy and nephropathy 19. history of coronary artery disease, cerebrovascular disease and peripheral artery disease 20. medication profiles 2: Correlation between blood glucose fluctuation range analyzed by FGM and various parameters as follow; 1. fasting plasma glucose 2. HbA1c 3. glycated albumin 4. systolic blood pressure 5. diastolic blood pressure 6. serum lipid profiles 7. eGFR (ml/min/1.73m2) 8. Liver function: AST, ALT, GGT 9. weight, BMI 10. serum Albumin 11. ACR(Urinary-albumin/creatinine ratio) 12. T-Bil 13. HOMA-R 14. hs-CRP 15. mean-IMT, max-IMT, plaque score 16. ABI, baPWV 17. counts of leukocyte and its fraction 18. history of retinopathy, neuropathy and nephropathy 19. history of coronary artery disease, cerebrovascular disease and peripheral artery disease 20. medication profiles	—

Measure

Time frame

1: Correlation between AGE measurements using the fingertip AGE sensor and various parameters as follow; 1. fasting plasma glucose 2. HbA1c 3. glycated albumin 4. systolic blood pressure 5. diastolic blood pressure 6. serum lipid profiles 7. eGFR (ml/min/1.73m2) 8. Liver function: AST, ALT, GGT 9. weight, BMI 10. serum Albumin 11. ACR(Urinary-albumin/creatinine ratio) 12. T-Bil 13. HOMA-R 14. hs-CRP 15. mean-IMT, max-IMT, plaque score 16. ABI, baPWV 17. counts of leukocyte and its fraction 18. history of retinopathy, neuropathy and nephropathy 19. history of coronary artery disease, cerebrovascular disease and peripheral artery disease 20. medication profiles 2: Correlation between blood glucose fluctuation range analyzed by FGM and various parameters as follow; 1. fasting plasma glucose 2. HbA1c 3. glycated albumin 4. systolic blood pressure 5. diastolic blood pressure 6. serum lipid profiles 7. eGFR (ml/min/1.73m2) 8. Liver function: AST, ALT, GGT 9. weight, BMI 10. serum Albumin 11. ACR(Urinary-albumin/creatinine ratio) 12. T-Bil 13. HOMA-R 14. hs-CRP 15. mean-IMT, max-IMT, plaque score 16. ABI, baPWV 17. counts of leukocyte and its fraction 18. history of retinopathy, neuropathy and nephropathy 19. history of coronary artery disease, cerebrovascular disease and peripheral artery disease 20. medication profiles

—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Kumamoto University Department of Metabolic Medicine, Faculty of Life Sciences

takeshim@gpo.kumamoto-u.ac.jp0963735169

Outcome results